Public Sector Pension Investment Board Has $13.34 Million Position in Amgen Inc. $AMGN

Public Sector Pension Investment Board boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 14.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,252 shares of the medical research company’s stock after acquiring an additional 5,917 shares during the quarter. Public Sector Pension Investment Board’s holdings in Amgen were worth $13,335,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Check Capital Management Inc. CA lifted its stake in shares of Amgen by 2.4% during the third quarter. Check Capital Management Inc. CA now owns 3,885 shares of the medical research company’s stock valued at $1,096,000 after acquiring an additional 90 shares during the period. Capital Investment Counsel LLC raised its holdings in Amgen by 2.1% during the 3rd quarter. Capital Investment Counsel LLC now owns 18,363 shares of the medical research company’s stock worth $5,182,000 after purchasing an additional 375 shares during the last quarter. ICW Investment Advisors LLC lifted its position in Amgen by 5.5% during the 3rd quarter. ICW Investment Advisors LLC now owns 9,259 shares of the medical research company’s stock valued at $2,613,000 after purchasing an additional 482 shares during the period. Wedbush Securities Inc. lifted its position in Amgen by 5.8% during the 3rd quarter. Wedbush Securities Inc. now owns 28,463 shares of the medical research company’s stock valued at $8,032,000 after purchasing an additional 1,557 shares during the period. Finally, Varma Mutual Pension Insurance Co boosted its stake in shares of Amgen by 8.9% in the 3rd quarter. Varma Mutual Pension Insurance Co now owns 89,259 shares of the medical research company’s stock valued at $25,189,000 after purchasing an additional 7,300 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.8%

AMGN stock opened at $369.19 on Monday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The stock has a market capitalization of $198.80 billion, a P/E ratio of 25.94, a P/E/G ratio of 3.78 and a beta of 0.46. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $385.12. The business has a 50-day moving average of $337.47 and a 200-day moving average of $313.77.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the firm posted $5.31 earnings per share. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.69% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on AMGN. DZ Bank raised their target price on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. BMO Capital Markets boosted their price objective on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Citigroup upped their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Piper Sandler lifted their price target on shares of Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Finally, Guggenheim boosted their price target on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Amgen has an average rating of “Moderate Buy” and an average price target of $354.04.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: European Commission approval for Uplinza (amifampridine) for generalized myasthenia gravis expands Amgen’s labelled indications in Europe and supports incremental near-term revenue potential for the product. Amgen wins EC approval for Uplinza in gMG
• Positive Sentiment: Amgen announced an increase to its dividend to $2.52, which boosts yield and signals management confidence in cash flow — typically supportive for a large-cap, dividend-oriented stock. Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
• Positive Sentiment: Unusually large call-option activity (roughly 320,232 calls bought) points to short-term bullish positioning by some investors, which can amplify upside moves in the stock. (No source link provided in feed)
• Neutral Sentiment: Amgen will present at Citi’s 2026 Virtual Oncology Leadership Summit — a standard investor relations event that raises visibility on oncology programs but is not intrinsically catalytic. AMGEN TO PRESENT AT CITI’S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
• Neutral Sentiment: Analyst notes are mixed: Argus reiterated a Buy with a $400 target while Guggenheim reaffirmed a Hold — this provides conflicting signals but keeps the stock in analysts’ focus. Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Industry coverage (CNBC) on pharma’s resetting priorities — pricing, pipelines and patent cliffs — is a sector-level backdrop that could affect sentiment for large-cap drugmakers like Amgen but is not company-specific. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Recent entries on short interest in the data feed appear to be reporting zero shares / NaN changes (likely a reporting glitch) and do not signal a meaningful rise in short positioning. (No link provided)

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.